---
title: "IRulya Therapeutics (IRLA) news: offering and Nasdaq notice"
url: "https://aibio.space/companies/irulya-therapeutics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "IRLA offering and Nasdaq notice news: Quince Therapeutics (now IRulya) agrees to $11.5 million private placement. IRulya Therapeutics Inc."
---

IRLA IRulya Therapeutics Inc. NASDAQ · United States

# IRulya Therapeutics (IRLA) news IRLA offering and Nasdaq notice news

Listings · 2026-09-04

## [Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice](https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-gets-nasdaq-stockholders/)

Nasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change.

## Latest IRulya Therapeutics news

1. 2026-04-01 Distress [Quince Therapeutics (now IRulya Therapeutics) files NT 10-K after Phase 3 miss and staff cuts](https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-files-nt-10-k-after-phase/) The company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25.
2. 2025-06-13 Financings [Quince Therapeutics (now IRulya) agrees to $11.5 million private placement](https://aibio.space/news/quince-therapeutics-now-irulya-agrees-11-5-million-private-placement/) Quince Therapeutics agreed to sell about $11.5 million of stock and warrants to institutional investors and three executives, and up to $10.4 million more depends on holders paying $1.20 per share.

## IRulya Therapeutics at a glance

- **Ticker**: IRLA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $116.0 million

### Related companies

- [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) NASDAQ: SNTI
- [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO
- [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX
- [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA
- [Regen Biopharma](https://aibio.space/companies/regen-biopharma/) OTC: RGBP
- [MULTICELL TECHNOLOGIES INC](https://aibio.space/companies/multicell-technologies/) OTC: MCET
- [Denali Therapeutics](https://aibio.space/companies/denali-therapeutics/) NASDAQ: DNLI
- [Disc Medicine](https://aibio.space/companies/disc-medicine/) NASDAQ: IRON

### Also on NASDAQ

- [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA
- [Bon Natural Life](https://aibio.space/companies/bon-natural-life/) BON
- [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) CURX
- [ANGIODYNAMICS INC](https://aibio.space/companies/angiodynamics/) ANGO
- [Kymera Therapeutics](https://aibio.space/companies/kymera-therapeutics/) KYMR
- [Gelteq](https://aibio.space/companies/gelteq/) GELS

## IRulya Therapeutics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$35.4 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) | [$18.6 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) |
| Net income (loss) | [-$84.0 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) | [-$56.8 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) |
| Cash from operations | [-$41.4 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) | [-$31.9 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) |
| Cash and equivalents | [$5.8 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526352201/) | [$6.2 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526151364/) |
| Short-term investments | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1662774/000119312526352201/) | [$34.6 million](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $116.0 million, plus short-term investments of $0, $116.0 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about IRulya Therapeutics

Has IRulya Therapeutics raised money recently?

Our latest story on this, dated Jun 13, 2025: "Quince Therapeutics (now IRulya) agrees to $11.5 million private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/quince-therapeutics-now-irulya-agrees-11-5-million-private-placement/).

Has IRulya Therapeutics received a Nasdaq deficiency notice?

Our latest story on this, dated Sep 4, 2026: "Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-gets-nasdaq-stockholders/).

What is the ticker symbol of IRulya Therapeutics?

IRulya Therapeutics Inc. trades under the ticker IRLA on NASDAQ.

Where is IRulya Therapeutics listed?

IRulya Therapeutics Inc. is listed on NASDAQ.

What is the SEC CIK of IRulya Therapeutics?

The SEC Central Index Key (CIK) for IRulya Therapeutics Inc. is 1662774. Its filings are on SEC EDGAR.

How many shares does IRulya Therapeutics have outstanding?

1,017,063 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14.

Which country or territory is IRulya Therapeutics listed under?

Our directory records IRulya Therapeutics Inc. under United States.

What does IRulya Therapeutics do?

Our directory classifies IRulya Therapeutics Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of IRulya Therapeutics?

The ISIN recorded for IRulya Therapeutics Inc. is US22053A3059.

Does aibio.space cover IRulya Therapeutics?

aibio.space lists IRulya Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is IRulya Therapeutics incorporated?

SEC records list its state or country of incorporation as DE.

Is IRulya Therapeutics profitable?

IRulya Therapeutics Inc. reported a net loss of $84.0 million for the fiscal year ended Dec 31, 2025, and used $41.4 million of cash in operations, per its annual report to the SEC.

How much does IRulya Therapeutics spend on research and development?

$35.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does IRulya Therapeutics have?

$116.0 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.

What is the latest IRulya Therapeutics (IRLA) stock news?

Our latest story on IRulya Therapeutics, dated Sep 4, 2026: "Quince Therapeutics (now IRulya Therapeutics) gets Nasdaq stockholders' equity deficiency notice". Nasdaq told Quince Therapeutics its stockholders' equity was ($35,324,000), below the $10,000,000 minimum. The company has until October 15, 2026 to submit a compliance plan and has filed an initial listing application that would come with a name change. [Source](https://aibio.space/news/quince-therapeutics-now-irulya-therapeutics-gets-nasdaq-stockholders/).

## Investor discussion: IRulya Therapeutics

Members talk about IRulya Therapeutics (IRLA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at IRulya Therapeutics, newest first. Each line links the filing it comes from.

1. 2026-10-06 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526415730/d115238d8k.htm)
2. 2026-09-14 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-ex99_1.htm)
3. 2026-09-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/d105528d8k.htm)
4. 2026-08-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526353141/d379347dex991.htm)
5. 2026-06-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526284089/d168420d8k.htm)
6. 2026-06-11 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526267862/d124733d8k.htm)
7. 2026-05-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526234858/d139014d8k.htm)
8. 2026-05-18 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526228133/d109149dex991.htm)
9. 2026-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/d623526d8k.htm)
10. 2026-04-27 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526182255/qncx-20260424.htm)
11. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526161838/qncx-20260417.htm)
12. 2026-04-09 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/d115661d8k.htm)
13. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526138017/d140699dnt10k.htm)
14. 2026-03-30 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526130489/d57124dex991.htm)
15. 2026-03-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526117794/d122428d8k.htm)
16. 2026-02-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312526047544/d89820d8k.htm)
17. 2025-10-17 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312525242511/d79739d424b5.htm)
18. 2025-08-05 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312525173623/d23741d424b5.htm)
19. 2025-06-13 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312525140873/d31831d8k.htm)
20. 2025-06-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000034/qncx-20250604.htm)
21. 2025-04-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000025/qncx-20250423.htm)
22. 2025-04-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000016/qncx-20250409.htm)
23. 2025-03-24 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000119312525061458/d926685d424b5.htm)
24. 2025-03-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000166277425000012/qncx-20241231.htm)
25. 2024-12-27 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1662774/000162828024052494/quincetherapeutics-424b5.htm)
26. 2024-11-14 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1662774/000166277424000013/qncx-20241112.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:IRLA on TradingView](https://www.tradingview.com/symbols/NASDAQ-IRLA/).

## SEC filings and registration

- **SEC name**: IRulya Therapeutics Inc.

- **CIK**: 1662774

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: IRLA (Nasdaq), QNCX (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510

- **Phone**: 203-208-8994

- **Shares outstanding**: 1,017,063 as of 2026-08-07 (10-Q filed 2026-08-14)

- **Former names**: Quince Therapeutics, Inc.; Cortexyme, Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526424731/d123526d8k.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526418538/d172110d8k.htm) filed 2026-10-09
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526415730/d115238d8k.htm) filed 2026-10-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526411260/d171747d8k.htm) filed 2026-10-02
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526390652/qncx-20260908.htm) filed 2026-09-14
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526382838/d105528d8k.htm) filed 2026-09-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1662774/000119312526371389/d124795d8k.htm) filed 2026-08-27
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1662774/000119312526364220/d46981ddef14a.htm) filed 2026-08-25

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001662774), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

IRulya Therapeutics Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker IRLA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: IRulya Therapeutics Inc.

- **Ticker**: IRLA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US22053A3059

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-IRLA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/irulya-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "IRulya Therapeutics (IRLA) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/irulya-therapeutics/